Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether the National Institute for Health and Care Excellence has had discussions with its counterparts in (a) Scotland, (b) Wales, and (c) Northern Ireland on recommending abiraterone acetate for NHS patients with high-risk, non-metastatic prostate cancer.

Decisions on the availability of medicines in Scotland, Wales, and Northern Ireland are a matter for the devolved administrations.